Preimplantation Genetic Diagnosis (PGD) With Gonadotropin-releasing Hormone (GnRH) Agonist Versus Antagonist
Launched by UNIVERSITAIR ZIEKENHUIS BRUSSEL · Jun 27, 2013
Trial Information
Current as of August 11, 2025
Completed
Keywords
ClinConnect Summary
Patients will be randomized at the outpatient clinic in two groups.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • ≤ 39 years the day of oocyte retrieval
- • BMI ≤ 29
- • cycle rank 1
- • menstrual cycle 25-36 days
- • PGD or preimplantation genetic screening (PGS) requested
- • ICSI
- • Single embryo transfer (SET) on day 5
- Exclusion Criteria:
- • Polycystic Ovary Syndrome (PCOS) (according Rotterdam criteria)
- • Hormonal disturbances
- • Endometriosis grade III and IV
About Universitair Ziekenhuis Brussel
Universitair Ziekenhuis Brussel (UZ Brussel) is a leading academic medical center in Belgium, renowned for its commitment to advancing healthcare through innovative research and clinical trials. As a prominent institution affiliated with the Vrije Universiteit Brussel, UZ Brussel integrates cutting-edge medical research with high-quality patient care. The hospital's multidisciplinary teams are dedicated to exploring novel therapeutic approaches and contributing to the development of evidence-based treatments, ensuring the highest standards of safety and efficacy in clinical research. With a strong focus on collaboration and knowledge dissemination, UZ Brussel plays a pivotal role in shaping the future of medicine and improving patient outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Brussels, , Belgium
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials